Quince Therapeutics, Inc
Price
FilingsNewest: 8-K, Director or officer changeOct 2 →InsidersNo open-market buys. 1 insider sold $173,500 in 1 sale, with no 10b5-1 plan named.→HoldersBalyasny 6.9%Ikarian Capital 7.1%Millennium 7.0%→Financing →PeersClosest companies: BIVI, ERNA, ATOS→
From the filings
Figures
- Net income
- −$92.5Mlast 12 months
- Operating cash flow
- −$39.5Mlast 12 months
- Cash and equivalents
- $116.0Mat the last balance sheet
- Total debt
- $0.00at the last balance sheet
- Shares outstanding
- 1.0M shareson issue